Table 2 Patient data.

From: Sclerotic bone: a sign of bone reaction in patients with medication related osteonecrosis of the jaw

Patient	Gender	Age at diagnosis	Underlying disease of intake	Bisphosphonate	Dosis	Duration of intake (months)	Number of lesions	MRONJ stage (AAOMS)	Localization	Sequester	Healed	Recidive	Postoperative imaging timepoint
1	Female	75	Breast cancer	Zolendronate	4 mg	276	1	I	Regio 34–37	no	no	yes	7 months
2	Male	71	Multiple myeloma	Zolendronate + Denosumab	4 mg	48	1	I	Regio 27	no	yes	no	4 months
3	female	47	Breast cancer	Denosumab	120 mg	84	1	II	Regio 37/38	no	no	yes	7 months
4	Female	55	Colon cancer	Zolendronate	4 mg	23	1	III	Regio 16/17 and 22	no	yes	yes, different location	8 months
5	male	58	Renal cell cancer	Zolendronate	4 mg	71	1	I	Regio 44–47	no	yes	no	18 months
6	Female	68	Breast cancer	Zolendronate	4 mg	42	1	III	Regio 16/17	no	yes	Yes, different location	80 months
7	Male	83	Multiple myeloma	Zolendronat	4 mg	54	1	I	Regio 44–48	no	yes	yes	6 months
8	Female	69	Osteoporosis	Zolendronate	4 mg	48	1	I	Regio 25–27	no	yes	no	12 months
9	Male	66	Prostate cancer	Zolendronate	4 mg	61	1	II	Regio 36–38	no	yes	yes	9 months
10	Female	56	Renal cell cancer	Pamidronat + Denosumab	-	95	1	II	Regio 34–37	no	yes	yes	19 months
11	Female	71	Breast cancer	Zoledronat	4 mg	108	1	II	Regio 45	no	yes	no	5 months
12	Female	62	Breast cancer	Denosumab	120 mg	58	1	III	Regio 22–25	no	yes	Yes, different location	5 months
13	Male	72	Prostate cancer	Zoledronat	4 mg	44	1	I	Regio 12–17	no	yes	no	5 months
14	Female	77	Osteoporosis	Denosumab	60 mg	80	1	II	Regio 47	no	yes	Yes, different location	9 months
15	Female	49	Breast cancer	Denosumab	120 mg	24	1	I	Regio 43	no	yes	yes	3 months
16	Male	72	Prostate cancer	Zolendronate	4 mg	-	1	I	Regio 36	no	yes	no	80 months
17	Female	66	Breast cancer	Pamidronat	30 mg	35	1	I	Regio 15–17	no	yes	no	5 months
18	male	72	Prostate cancer	Zolendronate	4 mg	48	1	III	Regio 35–38	yes	yes	no	6 months
19	male	86	Prostate cancer	Zolendronate	4 mg	138	1	II	Regio 44–48	yes	yes	no	6 months
20	Female	84	Breast cancer	Zolendronate	4 mg	36	1	III	Regio 34–38	no	yes	yes	7 months
21	Male	80	Multiple myeloma	Zolendronate	4 mg	36	2	I	Regio 35–38 and 12–15	no	yes	yes	10 months
22	female	83	Breast cancer	Denosumab	60 mg	60	1	I	Regio 32–34	no	yes	no	15 months
23	Male	72	Prostate cancer	Zolendronate	4 mg	45	1	I	Regio 38	no	yes	Yes, different location	34 months
24	Female	79	Osteoporsoe	Denosumab	60 mg	84	1	II	Regio 47	no	yes	Yes, different location	65 months
25	Female	80	Osteoporosis	Denosumab	60 mg	72	1	I	Regio 33–37	no	yes	Yes, different location	15 months
26	Male	72	Prostate cancer	Denosumab	120 mg	108	1	III	Regio 14–18	no	yes	no	6 months

Back to article page

Table 2 Patient data.

Search

Quick links